Critical review: Assessment of interferon-β Immunogenicity in multiple sclerosis

Journal of Interferon and Cytokine Research

Volumn 30, Issue 10, 2010, Pages 759-766

  Bendtzen, Klaus ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; INTERFERON BETA SERINE; JANUS KINASE 1; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; PROTEIN KINASE TYK2; PROTEIN P48;

ANTIBODY DETECTION; ANTIGEN BINDING; CLINICAL ASSESSMENT; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREACTIVITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SIGNAL TRANSDUCTION; THERAPY EFFECT; TREATMENT RESPONSE;

ANTIBODIES; ANTIBODIES, NEUTRALIZING; ANTIGEN-ANTIBODY REACTIONS; BIOLOGICAL ASSAY; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECOMBINANT PROTEINS;

EID: 77957352554     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2010.0091     Document Type: Review

References (46)

1. Ann Marrie R., Rudick RA 2006. Drug insight: interferon treatment in multiple sclerosis. Nat Clin Pract Neurol '2:34-44.
2. Bendtzen K. 2003. Anti-IFN BAb and NAb antibodies: a mini review. Neurology 61 (SUPPL. 5):S6-S10.
3. Bendtzen K, Ainsworth M, Steenholdt C., Thomsen OO, Brynskov J. 2009. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol '44:774-781.
4. Bendtzen K, Hansen MB, Ross C, Svenson M. 1998. High-avidity autoantibodies to cytokines. Immunol Today '19:209-211.
5. Bendtzen K, Hansen MB, Ross C, Svenson M. 2000. Detection of autoantibodies to cytokines. Mol Biotechnol '14:251-261.
6. Bendtzen K, Kromminga A. 2008. Immunogenicity of interferon-beta. In: van de Weert M, Møller EH, eds. Immunogenicity of Biopharmaceuticals, Vol. viii. New York: Springer, pp 127-136.
7. Bendtzen K, Svenson M. 2007. Cytokine autoantibodies. In: Shoenfeld Y, Meroni PL, Gershwin ME, eds. Autoantibodies. Elsevier Press, pp 299-307.
8. Bendtzen K, Svenson M, Jønsson V, Hippe E. 1990. Auto-antibodies to cytokines - friends or foes? Immunol Today 11:167-169.
9. Bertolotto A. 2009. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 277 (SUPPL. 1):S29-S32.
10. Casadevall N, Nataf J, Viron B., Kolta A, Kiladjian JJ, Martin-Dupont P, Michaud P., Papo T, Ugo V, Teyssandier I, Varet B, Mayeux P. 2002. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med '346:469-475. (Pubitemid 34441737)
11. European Medicines Agency (EMEA). 2007. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003946.pdf pp 1-18.
12. European Medicines Agency (EMEA). 2008. Biologics working party report to the CHMP. Beta-interferons and neutralising antibodies (in multiple sclerosis). www.emea.europa.eu/docs/en-GB/document-library/Report/2009/11/WC500015395.pdf pp 1-3.
13. Farrell R, Kapoor R, Leary S., Rudge P, Thompson A, Miller D., Giovannoni G. 2008. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of interferon-beta. Mult Scler '14: 212-218.
14. Francis GS, Rice GP, Alsop JC 2005. Interferon beta-1a in MS: results following development of neutralizing antibodies in prisms. Neurology '65:48-55.
15. Gibbs E, Oger J. 2008. A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res '28:713-723.
16. Gneiss C, Brugger M, Millonig A., Fogdell-Hahn A, Rudzki D, Hillert J., Berger T, Reindl M, Deisenhammer F. 2008. Comparative study of four different assays for the detection of binding antibodies against interferon-beta. Mult Scler '14:830-836.
17. Golgher RR, Redlich PN, Totti D.O., Grossberg SE 1999. Quantitative liquid-phase chemiluminescence ELISA: Detection of subtle epitope differences in huIFN-beta. J Interferon Cytokine Res '19:995-998.
18. Grossberg SE. 2003. Perspectives on the neutralization of interferons by antibody. Neurology '61:S21-S23.
19. Grossberg SE, Kawade Y, Grossberg LD 2009. The neutralization of interferons by antibody III. The constant antibody bioassay, a highly sensitive quantitative detector of low antibody levels. J Interferon Cytokine Res '29:93-104.
20. Grossberg SE, Kawade Y, Kohase M., Klein JP 2001. The neutralization of interferons by antibody II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res '21:743-755.
21. Hafler DA, Slavik JM, Anderson D.E., O'Connor KC, De Jager P, Baecher-Allan C. 2005. Multiple sclerosis. Immunol Rev '204:208-231.
22. Hartung H-P, Polman C., Bertolotto A, Deisenhammer F, Giovannoni G., Havrdova E, Hemmer B, Hillert J, Kappos L, Kieseier B, Killestein J, Malcus C, Comabella M, Pachner A, Schellekens H, Sellebjerg F, Selmaj K, Sorensen PS. 2007. Neutralising antibodies to interferon beta in multiple sclerosis: expert panel report. J Neurol '254:827-837.
23. Hyrich KL, Lunt M, Watson K.D., Symmons DP, Silman AJ 2007. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK National Cohort Study. Arthritis Rheum '56:13-20.
24. The IFNB Multiple Sclerosis Study Group. 1993. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology '43:655-661.
25. Kaliyaperumal A, Jing S. 2009. Immunogenicity assessment of therapeutic proteins and peptides. Curr Pharm Biotechnol '10:352-358.
26. Koren E, Smith HW, Shores E, Shankar G., Finco-Kent D, Rup B, Barrett Y.C., Devanarayan V., Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G. Zuckerman LA, Stebbins CC, Mire-Sluis A. 2008. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods '333:1-9.
27. Lallemand C, Meritet JF, Blanchard B, Lebon P., Tovey MG 2010. One-step assay for quantification of neutralizing antibodies to biopharmaceuticals. J Immunol Methods '356:18-28.
28. Lallemand C, Meritet JF, Erickson R, Grossberg S.E., Roullet E., Lyon-Caen O, Lebon P, Tovey MG 2008. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene. J Interferon Cytokine Res '28:393-404.
29. Lam R, Farrell R, Aziz T., Gibbs E, Giovannoni G, Grossberg S., Oger J. 2008. Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. J Immunol Methods '336:113-118.
30. Meager A. 1997. Natural autoantibodies to interferons. J Interferon Cytokine Res 17 (SUPPL. 1):S51-S53.
31. Meager A, Wadhwa M, Dilger P., Bird C, Thorpe R, Newsom-Davis J, Willcox N. 2003. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol '132:128-136.
32. Neumann TA, Foote M. 2000. Megakaryocyte growth and development factor (MGDF): an MPL ligand and cytokine that regulates thrombopoiesis. Cytokines Cell Mol Ther '6:47-56.
33. Pachner AR. 2003. Anti-IFNB antibodies in IFNB-treated MS patients. Neurology 61 (SUPPL. 5):S1-S5.
34. Pachner AR, Dail D, Pak E., Narayan K. 2005. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol '166:180-188.
35. Pestka S, Krause CD, Walter MR 2004. Interferons, interferon-like cytokines, and their receptors. Immunol Rev '202:8-32.
36. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M., Ross C, Sorensen PS, The Danish Multiple Sclerosis Group. 2006. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler '12:247-252.
37. Pipe SW. 2005. The promise and challenges of bioengineered recombinant clotting factors. J Thromb Haemost '3:1692-1701.
38. Polman CH, Schellekens H, Killestein J. 2006. Neutralizing antibodies to interferon-beta may persist after cessation of therapy: what impact could they have? Mult Scler 12:245-246.
39. Ravnborg M, Bendtzen K, Christensen O., Jensen PEH, Hesse D, Tovey M.G., Sorensen PS. 2009. Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bio-activity in anti-interferon beta antibody-positive patients with multiple sclerosis. Mult Scler '15:323-328.
40. Ross C, Clemmesen KM, Svenson M, Sorensen P.S., Koch-Henriksen N, Skovgaard GL, Bendtzen K. 2000. Immunogenicity of interferon-B in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol '48:706-712.
41. Ross C, Svenson M, Clemmesen K.M., Sorensen PS, Koch-Henriksen N, Bendtzen K. 2006. Measuring and evaluating interferon-beta-induced antibodies in patients with multiple sclerosis. Mult Scler '12:39-46.
42. Rutgeerts P, Vermeire S, van Assche G. 2010. Predicting the response to infliximab from trough serum levels (commentary). Gut 59:7-8.
43. Sorensen PS, Koch-Henriksen N, Ross C., Clemmesen KM, Bendtzen K, The Danish Multiple Sclerosis Study Group. 2005. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology '65:33-39.
44. Sorensen PS, Ross C, Clemmesen K.M., Bendtzen K., Frederiksen JL, Jensen K, Kristensen O, Petersen T., Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N, Danish Multiple Sclerosis Study Group. 2003. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet '362:1184-1191.
45. Sorensen PS, Tscherning T, Mathiesen H.K., Langkilde AR, Ross C, Ravnborg M, Bendtzen K. 2006. Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology 67:1681-1683.
46. Strand V, Kimberly R, Isaacs JD 2007. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov '6:75-92.